Bildkälla: Stockfoto

Spago Nanomedical: Q2 ’21: Our comment - Redeye

Redeye comments on Spago Nanomedical's Q2 report, which came without any surprises. We judge the market has lost sight of Spago and that the share could rally to our Base Case upon SpagoPix licensing and Tumorad entering the clinic.

Redeye comments on Spago Nanomedical's Q2 report, which came without any surprises. We judge the market has lost sight of Spago and that the share could rally to our Base Case upon SpagoPix licensing and Tumorad entering the clinic.
Börsvärldens nyhetsbrev
ANNONSER